Korean Drug Co. Ltd (014570) - Total Liabilities

Latest as of September 2025: ₩14.01 Billion KRW ≈ $9.50 Million USD

Based on the latest financial reports, Korean Drug Co. Ltd (014570) has total liabilities worth ₩14.01 Billion KRW (≈ $9.50 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Korean Drug Co. Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how Korean Drug Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See Korean Drug Co. Ltd (014570) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Korean Drug Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Korean Drug Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Aetherium Acquisition Corp NASDAQ:GMFI	USA	$10.13 Million
Tai Twun Enterprise Co Ltd TW:3432	Taiwan	NT$75.69 Million
Ginegar TA:GNGR	Israel	ILA451.28 Million
Skye Bioscience, Inc. Common Stock NASDAQ:SKYE	USA	$10.40 Million
Cadence Opportunities Fund Ltd AU:CDO	Australia	AU$13.30 Million
DNXcorp PA:ALDNX	France	€12.05 Million
Almaden Minerals Ltd TO:AMM	Canada	CA$17.63 Million
EMB Mission Bound AB (publ) ST:NAVIGO-STAM	USA	Skr376.93 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Korean Drug Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 014570 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	7.25	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.17	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.15	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Korean Drug Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Korean Drug Co. Ltd (2014–2024)

The table below shows the annual total liabilities of Korean Drug Co. Ltd from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩10.78 Billion ≈ $7.31 Million	-14.56%
2023-12-31	₩12.62 Billion ≈ $8.55 Million	+28.72%
2022-12-31	₩9.80 Billion ≈ $6.64 Million	-17.77%
2021-12-31	₩11.92 Billion ≈ $8.08 Million	-4.42%
2020-12-31	₩12.47 Billion ≈ $8.45 Million	+15.50%
2019-12-31	₩10.80 Billion ≈ $7.32 Million	+6.27%
2018-12-31	₩10.16 Billion ≈ $6.89 Million	+3.48%
2017-12-31	₩9.82 Billion ≈ $6.66 Million	+0.73%
2016-12-31	₩9.75 Billion ≈ $6.61 Million	+2.42%
2015-12-31	₩9.52 Billion ≈ $6.45 Million	-28.88%
2014-12-31	₩13.38 Billion ≈ $9.07 Million	--

About Korean Drug Co. Ltd

KQ:014570 Korea Drug Manufacturers - General

Market Cap

$24.86 Million

₩36.68 Billion KRW

Market Cap Rank

#24424 Global

#1715 in Korea

Share Price

₩3390.00

Change (1 day)

-2.31%

52-Week Range

₩3120.00 - ₩4910.00

All Time High

₩13030.58